openPR Logo
Press release

Antioxidants May Aid in the Treatment of Tardive Dyskinesia

05-10-2019 09:57 AM CET | Health & Medicine

Press release from: Physicians Postgraduate Press

Memphis, TN (May 9, 2019) – Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the prevention and treatment of tardive dyskinesia due to the oxidative stress hypothesis.

This case report describes a man in his 30s with a diagnosis of schizoaffective disorder–bipolar type who began exhibiting involuntary movements of the tongue, lips, and truncal area. While initial agents did not completely improve involuntary movements, combining them with antioxidants such as omega-3/DHA/EPA/DPA, vitamin B6, and melatonin lowered symptom severity. Thus, alternative treatment options may be considered before use of more expensive agents for mild cases of tardive dyskinesia.
Access the entire case report, “Antioxidants for the Treatment of Tardive Dyskinesia: AIMing to Find the Best Treatment Option,” by O. Greg Deardorff, PharmD, BCPP; Kimberly A. Ehrhard, PharmD; Jason Cafer, MD; and Beth M. Hall, PharmD, BCPP, at

The Primary Care Companion for CNS Disorders (PCC) is an international, peer-reviewed, online-only journal, published by Physicians Postgraduate Press, Inc. Its mission is to advance the clinical expertise of primary care physicians and other health care professionals who treat patients with mental and neurologic illnesses. PCC is indexed by the National Library of Medicine.

Sallie Gatlin
Physicians Postgraduate Press
PO Box 752870
Memphis, Tennessee 38175-2870
(901) 273-2753

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antioxidants May Aid in the Treatment of Tardive Dyskinesia here

News-ID: 1733703 • Views:

More Releases from Physicians Postgraduate Press

New Detailed Review of Oral Ketamine for Depression Published in JCP
Memphis, TN (April 16, 2019) – A review article published today in The Journal of Clinical Psychiatry indicates that orally administered ketamine is efficacious for depression but may take longer to yield results. The review, authored by Joshua D. Rosenblat and colleagues at the University of Toronto, analyzed 13 articles, including 2 randomized controlled trials (RCTs). The RCTs demonstrated antidepressant efficacy and good tolerability for oral ketamine, but significant changes
Immigrants at Lower Risk of Substance Use, Psychiatric Disorders Than US-Born Counterparts
Immigrants at Lower Risk of Substance Use, Psychiatric Disorders Than US-Born Co …
Memphis, TN (February 28, 2019) – Today The Primary Care Companion for CNS Disorders published a study comparing prevalence rates of alcohol, nicotine, and other drug use and major psychiatric disorders between US-born and foreign-born Mexican Americans and non-Hispanic whites. Hispanics are the leading ethnic majority in the US, and Mexican Americans constitute 60% of the US Hispanic population. Therefore, focus on this group is timely and important, especially since

More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025:  …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market. Description The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries". The Global Primary Cells
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
01-25-2017 | Health & Medicine
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes